Search companies

Live

ENTROPY NEURODYNAMICS LIMITED (ASX: ENP)

Health care · News and insights

Price unavailable

Latest ENP announcements

Announcement Insights

Entropy Reports Sustained Binge-Eating Study Gains as TRP-8803 Trials Expand

Entropy reported that all six patients in the first treatment-resistant binge-eating cohort maintained clinically meaningful improvement at 12 weeks, with weekly episodes 73% below baseline, as it advanced plans for broader TRP-8803 testing. Ethics approval was secured for a 72-patient study across eight indications, and the next cohort began testing a shorter infusion protocol, with topline results expected by the end of 2026. A South African patent granted in November protects specified psilocin crystalline forms through 2043, adding to an Australian patent granted earlier in 2026.

Updated 13 Nov 2026, 10:39 AM Sydney time
Share
SourcesChange of Company ConstitutionResults of AGMEntropy Secures South African Psilocin Patent to 2043Quarterly Activities Report and Appendix 4C
Comments

Entropy Neurodynamics Shareholders Pass All AGM Resolutions

2026-11-12 · Health care

ENP: $0.029 +0.00% · MC: $47M

Entropy Neurodynamics said all resolutions at its annual meeting were carried by the required majorities, including the re-election of director Chris Ntoumenopoulos and approval of a 10% placement facility. The meeting also passed a non-binding resolution to adopt the remuneration report.

Updated 2026-11-12 16:54
Share
SourcesResults of AGM
Comments

Entropy Wins South African Psilocin Patent Protection Through 2043

2026-11-09 · Health care

ENP: $0.029 +0.00% · MC: $47M

Entropy Neurodynamics has secured a South African patent covering proprietary crystalline forms of psilocin, extending protection through 2043 and adding to a corresponding Australian patent granted earlier this year. The company says the patent complements its TRP-8803 development program and is intended to support future development, licensing and partnership opportunities.

Updated 2026-11-09 09:03
Share
SourcesEntropy Secures South African Psilocin Patent to 2043
Comments

Entropy reports sustained improvement in binge-eating study as it expands TRP-8803 trials

2026-10-28 · Health care

ENP: $0.030 +0.00% · MC: $47M

Entropy Neurodynamics reported that all six patients in the first cohort of its treatment-resistant binge-eating study maintained clinically meaningful improvement at 12 weeks, with half experiencing complete remission and weekly binge-eating episodes remaining 73% below baseline. The company also secured ethics approval for a 72-patient study across eight indications, agreed GMP manufacturing with BioCina and signed a preliminary agreement with UCSF for a potential US depression study. After quarter-end, the next study cohort began testing a shorter infusion protocol, with topline results expected by the end of 2026.

Updated 2026-10-28 08:37
Share
SourcesQuarterly Activities Report and Appendix 4C
Comments